VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.

Purpose: To evaluate the effect of vitreomacular traction (VMT) on visual acuity outcomes and central retinal thickness (CRT) measurements after intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for treatment of exudative age-related macular degeneration (AMD).

Methods: In this retrospective series, the authors evaluate the clinical records and optical coherence tomography of 34 eyes of 32 patients, with VMT confirmed on optical coherence tomography at baseline, to assess the effects of VMT on anti-VEGF therapy for newly diagnosed exudative wet AMD. Best-corrected visual acuity at baseline, 1, 3, 6, 9, and 12 months and CRT at baseline, 3, 6, and 12 months were assessed.

High altitude and retinal detachment.

We describe the case of a 38-year-old man who presented with bilateral retinal detachments following a trek in Tibet during which time he took acetazolamide for prophylaxis of acute mountain sickness (AMS). This is the first time that retinal detachment has been described following a sojourn to high altitude. Acetazolamide has not been previously associated with retinal detachment when used for prophylaxis of AMS or indeed during its many ophthalmic applications.